1. Home
  2. GBTG vs ERAS Comparison

GBTG vs ERAS Comparison

Compare GBTG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Business Travel Group Inc.

GBTG

Global Business Travel Group Inc.

HOLD

Current Price

$9.34

Market Cap

4.9B

Sector

Technology

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$13.82

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBTG
ERAS
Founded
2014
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.5B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
GBTG
ERAS
Price
$9.34
$13.82
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$8.92
$14.25
AVG Volume (30 Days)
5.5M
4.0M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
173.33
36.23
EPS
0.10
N/A
Revenue
$2,718,000,000.00
N/A
Revenue This Year
$21.78
N/A
Revenue Next Year
$4.29
N/A
P/E Ratio
$93.40
N/A
Revenue Growth
12.17
N/A
52 Week Low
$4.96
$1.24
52 Week High
$9.54
$24.28

Technical Indicators

Market Signals
Indicator
GBTG
ERAS
Relative Strength Index (RSI) 75.48 58.56
Support Level $9.34 $12.91
Resistance Level $9.46 $16.14
Average True Range (ATR) 0.06 0.84
MACD -0.12 0.54
Stochastic Oscillator 13.16 78.97

Price Performance

Historical Comparison
GBTG
ERAS

About GBTG Global Business Travel Group Inc.

Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: